Open Access

PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules

  • Authors:
    • Javad Garousi
    • Ken G. Andersson
    • Bogdan Mitran
    • Marie-Louise Pichl
    • Stefan Ståhl
    • Anna Orlova
    • John Löfblom
    • Vladimir Tolmachev
  • View Affiliations

  • Published online on: February 2, 2016     https://doi.org/10.3892/ijo.2016.3369
  • Pages: 1325-1332
  • Copyright: © Garousi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor, which is overexpressed in many types of cancer. The use of EGFR-targeting monoclonal antibodies and tyrosine-kinase inhibitors improves significantly survival of patients with colorectal, non-small cell lung cancer and head and neck squamous cell carcinoma. Detection of EGFR overexpression provides important prognostic and predictive information influencing management of the patients. The use of radionuclide molecular imaging would enable non-invasive repeatable determination of EGFR expression in disseminated cancer. Moreover, positron emission tomography (PET) would provide superior sensitivity and quantitation accuracy in EGFR expression imaging. Affibody molecules are a new type of imaging probes, providing high contrast in molecular imaging. In the present study, an EGFR-binding affibody molecule (ZEGFR:2377) was site-specifically conjugated with a deferoxamine (DFO) chelator and labelled under mild conditions (room temperature and neutral pH) with a positron-emitting radionuclide 89Zr. The 89Zr-DFO-ZEGFR:2377 tracer demonstrated specific high affinity (160±60 pM) binding to EGFR-expressing A431 epidermoid carcinoma cell line. In mice bearing A431 xenografts, 89Zr-DFO-ZEGFR:2377 demonstrated specific uptake in tumours and EGFR-expressing tissues. The tracer provided tumour uptake of 2.6±0.5% ID/g and tumour-to-blood ratio of 3.7±0.6 at 24 h after injection. 89Zr-DFO-ZEGFR:2377 provides higher tumour-to-organ ratios than anti-EGFR antibody 89Zr-DFO-cetuximab at 48 h after injection. EGFR‑expressing tumours were clearly visualized by microPET using 89Zr-DFO-ZEGFR:2377 at both 3 and 24 h after injection. In conclusion, 89Zr-DFO-ZEGFR:2377 is a potential probe for PET imaging of EGFR-expression in vivo.
View Figures
View References

Related Articles

Journal Cover

April-2016
Volume 48 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Garousi J, Andersson KG, Mitran B, Pichl M, Ståhl S, Orlova A, Löfblom J and Tolmachev V: PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. Int J Oncol 48: 1325-1332, 2016.
APA
Garousi, J., Andersson, K.G., Mitran, B., Pichl, M., Ståhl, S., Orlova, A. ... Tolmachev, V. (2016). PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules. International Journal of Oncology, 48, 1325-1332. https://doi.org/10.3892/ijo.2016.3369
MLA
Garousi, J., Andersson, K. G., Mitran, B., Pichl, M., Ståhl, S., Orlova, A., Löfblom, J., Tolmachev, V."PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules". International Journal of Oncology 48.4 (2016): 1325-1332.
Chicago
Garousi, J., Andersson, K. G., Mitran, B., Pichl, M., Ståhl, S., Orlova, A., Löfblom, J., Tolmachev, V."PET imaging of epidermal growth factor receptor expression in tumours using 89Zr-labelled ZEGFR:2377 affibody molecules". International Journal of Oncology 48, no. 4 (2016): 1325-1332. https://doi.org/10.3892/ijo.2016.3369